Evidence map›Paper›PMID 41075099›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Neural Networks to Calculate CDK2 Inhibition.

Walter Filgueira de Azevedo

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Walter Filgueira de AzevedoDepartment of Physics, Institute of Exact Sciences, Federal University of Alfenas, Alfenas, MG, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin-dependent kinase 2 (CDK2) participates in eukaryotic cell-cycle progression. CDK2's role in the cell cycle indicates that this enzyme is a target for anticancer drugs. Available high-resolution X-ray crystallographic structures and binding affinity data made it possible to construct machine learning models to predict affinity based on atomic coordinates. This work focuses on a workflow to integrate docking results generated with Molegro Virtual Docker (MVD) and experimental data to generate a neural-network model to calculate CDK2 inhibition. It integrates MVD and Molegro Data Modeller using Jupyter Notebooks and employs binding data from BindingDB ( https://www.bindingdb.org/ ) to train machine learning models. The model built using an integrated workflow shows superior predictive performance compared with a classical scoring function. This workflow can manage any target for which structural and binding data are known. The flexibility of the present approach can take experimental structures (e.g., crystallographic structures) and computational models (e.g., AlphaFold models). All CDK2 datasets and Jupyter Notebooks discussed in this work are available at GitHub: https://github.com/azevedolab/docking#readme .

Indexed as

Cyclin-Dependent Kinase 2Neural Networks, ComputerProtein Kinase InhibitorsBinding SitesCrystallography, X-RayHumansMachine LearningMolecular Docking SimulationProtein BindingSoftwareCDK2 protein, humanCyclin-Dependent Kinase 2Protein Kinase InhibitorsArtificial intelligenceCyclin-dependent kinase 2Machine learningMolegro virtual dockerNeural networkScoring function space

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.